» Articles » PMID: 27126492

The Long-term Prognosis of Cardiovascular Disease and All-cause Mortality for Metabolically Healthy Obesity: a Systematic Review and Meta-analysis

Overview
Specialty Health Services
Date 2016 Apr 30
PMID 27126492
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metabolically healthy obese phenotype (MHO) refers to obese individuals with absence of metabolic abnormalities such as dyslipidaemia, insulin resistance and hypertension. Many studies reported the long-term prognosis of MHO on diseases and mortality with inconsistent results.

Methods: We performed a meta-analysis to assess the risks of cardiovascular (CV) events and all-cause mortality for MHO individuals. Original prospective observational studies were searched in Medline, EMBASE, Web of Science and Cochrane library up to 30 September 2015. In this meta-analysis, the relative risk (RR) calculated on the basis of the incident number of disease events and deaths in participants and the corresponding multivariable-adjusted HR were both extracted to calculate pooled risk estimates. A random-effects model was used if there was heterogeneity among studies; otherwise, the fixed-effects model was used.

Results: 22 prospective studies, involving 584 799 participants, were archived in the analyses. With metabolically healthy normal weight as the reference, the MHO phenotype was associated with a higher risk of CV events (RR 1.50, 95% CI 1.27 to 1.77; HR 1.60, 95% CI 1.38 to 1.84). However, MHO individuals were not associated with increased risk of all-cause mortality (RR 1.18, 95% CI 0.83 to 1.66; HR 1.07, 95% CI 0.92 to 1.25).

Conclusions: The meta-analysis confirms a positive association between a metabolically healthy obese phenotype and the risk of CV events. However, higher risk for all-cause mortality is not evident in metabolically healthy obese individuals.

Citing Articles

Obesity, Metabolic Health, and Diabetic Complications in People With Type 1 Diabetes.

Mao Y, Gau J, Jiang N Endocrinol Diabetes Metab. 2024; 8(1):e70017.

PMID: 39679900 PMC: 11648318. DOI: 10.1002/edm2.70017.


Serum selenium accelerates the development of metabolic disorders in a metabolically healthy obese U.S. population: a retrospective cross-sectional analysis of a population-based study from the NHANES (2011-2018).

Li B, Chen J, Ma H, Yu Y, He S, Yang L Front Immunol. 2024; 15:1398299.

PMID: 39267744 PMC: 11390505. DOI: 10.3389/fimmu.2024.1398299.


Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.

Gallo G, Desideri G, Savoia C Nutrients. 2024; 16(16).

PMID: 39203917 PMC: 11356794. DOI: 10.3390/nu16162781.


Comparison of cardiovascular disease risk association with metabolic unhealthy obesity identified by body fat percentage and body mass index: Results from the 1999-2020 National Health and Nutrition Examination Survey.

Xiong Q, Zhang Y, Li J, An Y, Yu S PLoS One. 2024; 19(8):e0305592.

PMID: 39141628 PMC: 11324142. DOI: 10.1371/journal.pone.0305592.


Risk of Cardiovascular Events in Metabolically Healthy Overweight or Obese Adults: Role of LDL-Cholesterol in the Stratification of Risk.

Palatini P, Virdis A, Masi S, Mengozzi A, Casiglia E, Tikhonoff V Diagnostics (Basel). 2024; 14(13).

PMID: 39001205 PMC: 11240609. DOI: 10.3390/diagnostics14131314.